BlueCross BlueShield of Tennessee is implementing a new medical policy for Faricimab-svoa (Vabysmo™) effective December 1, 2026. The policy covers three FDA-approved indications (diabetic macular edema, neovascular wet age-related macular degeneration, and macular edema following retinal vein occlusion) with 12-month authorization periods and requires step therapy. This is a future-dated policy requiring advance preparation for implementation.
Get alerts when payers change rules like this one
We check BCBS Tennessee and other payers every day and email you when a change matches your specialty and state.
01Billing and prior authorization teams must prepare systems for the Vabysmo™ policy implementation.
02Review the Step Therapy Requirements document at https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf to understand mandatory step therapy prerequisites before claims can be approved.
03Update billing software to require prior authorization for all Vabysmo™ claims with 12-month authorization periods for the three covered indications.
04Configure system to limit prescribers to ophthalmologists or consultations with ophthalmologists only.
05Train front-desk and authorization staff on the three covered indications and step therapy requirements.
06Ensure denial logic for experimental/investigational uses (off-label indications not meeting Tennessee state mandate criteria).
07Claims submitted without proper step therapy completion and authorization will be denied.
Original notice
Faricimab-svoa (Vabysmo™)
bcbst.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.